09:14 AM EDT, 03/31/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Monday its board has authorized the repurchase of up to $50 million of its common stock through March 27, 2026.

The new stock buyback program may be suspended or discontinued at any time, the vaccines and specialty medicines company said, adding it had around 54.3 million shares outstanding at the end of 2024.

Emergent shares were ahead 3% in Monday's premarket activity.